Dr Reddys Laboratories Ltd Hits Intraday Low Amid Price Pressure on 9 Jul 2026

Intraday Performance and Price Movement

The pharmaceutical giant's shares declined sharply during the trading session, reaching an intraday low of Rs 1301, down 3.54% from the previous close. This drop contributed to a day change of -3.61%, underperforming the Pharmaceuticals & Biotechnology sector by 5.56%. The stock’s performance contrasted markedly with the broader market, where the Sensex advanced by 0.84%, closing at 77,144.47 points after a flat opening.

Dr Reddys Laboratories Ltd has now recorded four consecutive days of losses, cumulatively falling 5.28% over this period. This sustained downward trend highlights immediate pressures weighing on the stock amid a market environment where mega-cap stocks are generally leading gains.

Technical Indicators and Moving Averages

From a technical standpoint, the stock is trading above its 100-day and 200-day moving averages, signalling some underlying long-term support. However, it remains below its 5-day, 20-day, and 50-day moving averages, indicating short- to medium-term weakness and a lack of upward momentum in recent sessions.

Technical summaries show a mixed picture: daily moving averages are bullish, while weekly and monthly indicators such as MACD and KST remain bullish, but momentum oscillators like RSI show no clear signal. Bollinger Bands suggest mild bullishness on weekly and monthly charts, yet the absence of a clear trend in Dow Theory and On-Balance Volume (OBV) points to a lack of decisive directional conviction.

Comparative Performance Analysis

Examining Dr Reddys Laboratories Ltd’s recent performance relative to the Sensex reveals a nuanced picture. Over the past week, the stock declined by 3.51%, while the Sensex fell by 0.45%. Over one month, the stock gained 2.38%, lagging behind the Sensex’s 4.38% rise. However, over three months, the stock outperformed the benchmark with a 7.15% gain versus the Sensex’s 0.68%.

Longer-term returns show the stock has delivered 2.32% over the past year compared to the Sensex’s negative 7.64%, and year-to-date gains of 2.20% against the Sensex’s decline of 9.46%. Over three years, Dr Reddys Laboratories Ltd has outpaced the Sensex with a 25.33% return versus 18.19%, though over five and ten years, the Sensex’s returns of 47.28% and 184.42% respectively have been substantially higher than the stock’s 18.96% and 82.67%.

Market Context and Sector Dynamics

On 9 Jul 2026, the Sensex opened flat but gained momentum to close with a 0.84% increase, supported by mega-cap stocks. The index is trading above its 50-day moving average, although the 50DMA remains below the 200DMA, indicating a cautious medium-term outlook for the broader market. In contrast, Dr Reddys Laboratories Ltd’s underperformance highlights sector-specific or stock-specific pressures that have outweighed the general market optimism.

The Pharmaceuticals & Biotechnology sector, while generally stable, saw Dr Reddys Laboratories Ltd lag behind by 5.56% on the day, suggesting that the stock faced particular selling pressure or profit-taking activity not reflected across the sector.

Mojo Score and Rating Update

Dr Reddys Laboratories Ltd currently holds a Mojo Score of 58.0, categorised as a Hold rating. This represents a downgrade from its previous Buy rating as of 4 May 2026. The stock is classified as a large-cap within the Pharmaceuticals & Biotechnology sector, reflecting its significant market capitalisation and established presence.

The rating adjustment and score reflect a tempered outlook based on recent price action and technical signals, underscoring the cautious sentiment prevailing among market participants.

Summary of Immediate Pressures

The stock’s decline to its intraday low of Rs 1301 amid a broadly positive market environment points to specific pressures impacting Dr Reddys Laboratories Ltd. These include short-term technical weakness, as evidenced by its position below key moving averages, and a four-day losing streak that has eroded recent gains.

Despite the stock’s longer-term bullish technical indicators on weekly and monthly charts, the absence of clear momentum signals such as RSI and Dow Theory trends suggests a lack of conviction among traders in the near term. This has contributed to the price pressure observed during the session.

Overall, the stock’s intraday low and underperformance relative to both the sector and the Sensex highlight the challenges it faces in maintaining upward momentum amid a market led by mega-cap strength.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →